G-beta-gamma regulated phosphatidylinositol-3'kinase
AssigneeOnyx Pharmaceuticals, Inc.
InventorsLen Stephens, Phillip Thomas Hawkins
Life of this patent
Estimating the term…
Loading patent…
AssigneeOnyx Pharmaceuticals, Inc.
InventorsLen Stephens, Phillip Thomas Hawkins
Estimating the term…
The present invention relates to the discovery, identification and characterization of nucleotides that encode the G protein regulated phosphatidylinositol-3'kinase, a heterodimeric enzyme which produces the intracellular messenger phosphatidylinositol (3,4,5)-triphosphate in response to activation of trimeric G protein-linked receptors. This novel protein, comprised of a catalytic subunit, p120, and a regulatory subunit, p101, is found in cells of hematopoietic origin and is involved in immune system responses which cause inflammation. The presence of p101 subunit is largely responsible for the dramatic stimulation of kinase activity in the presence of activated trimeric G proteins. The invention encompasses p101 and p120 nucleotides, host cell expression systems, p101 and p120 proteins, fusion proteins, polypeptides and peptides, antibodies to these proteins, transgenic animals that express a p101 or 120 transgene, or recombinant knockout cells and animals that do not express the p101 or p120 gene, antagonists and agonists of the enzyme, and other compounds that modulate p101 or p120 gene expression or enzyme activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of inflammatory disorders.
A method for screening compounds useful for the treatment of inflammatory response disorders, comprising
Dependencies are inferred from the claim text.